Jan 02
Osteoporosis drugs misleading
Results of a study done by Barcellonian Dr. Pablo Alonso-Coello and another doctor on the effectiveness and the risks of taking bone-strengthening drugs for women with weakened bones but no osteoporosis, will be published on the January 19th issue of the BMJ.
According to the study, although bone-strengthening drugs (i.e. raloxifene, alendronate, risedronate), reduce the risk of fractures of women with osteoporosis, drug companies exaggerate their claims so that even women with only a low risk for osteoporosis are enticed to take them. The drug treatment becoming useless as it provides almost no benefit.
The study also focuses on the imminent harmful side effects of said drugs. One example is that there is no mention during a re-analysis of data that Raloxifene is found to increase risk of blood clots.
Source: HealthDay